Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the US Food and Drug Administration (FDA) for its in-house developed drug, Beizary, a modified version of docetaxel, which is indicated for the treatment of various cancers including breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, prostate cancer, and gastric cancer.
Docetaxel, a widely utilized anti-tumor drug in clinical settings, contains Tween 80, a non-ionic surfactant and emulsifier that has been associated with serious side effects such as allergies and fluid retention. As a result, all marketed docetaxel products carry black box warnings in their instructions regarding the safety issues related to Tween 80. In contrast, Beizary is formulated without Tween 80, thereby eliminating the severe allergic reactions associated with it and significantly enhancing clinical safety. Clinical trials have demonstrated that Beizary significantly reduces the blood toxicity associated with docetaxel and overall improves the drug’s clinical risk-benefit profile.- Flcube.com
